← Beta Bionics, Inc. Common Stock overview

Beta Bionics, Inc. Common Stock vs Zhonghong Pulin Medical Products: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Beta Bionics, Inc. Common Stock (BBNX)

Q3 202625 Jul – 29 Sep 2026

▼2▲1

Mint pump cleared, but dilution and guidance cut weigh on BBNX

Fair value cut on medtech valuation reset Analysts slashed Beta Bionics' fair value estimate to $19.80 from $31.30, citing slower revenue growth, thinner profit margins and a much lower assumed future P/E multiple. This reset reflects broad medtech sector headwinds and pulled the stock's perceived worth down, even as some banks raised targets.
It explains the sharp drop in the stock's assessed value and the cautious backdrop for BBNX.
$125M stock offering dilutes shareholders Beta Bionics announced a $125 million public offering of new common stock, with an option for underwriters to buy up to $18.75 million more. Selling new shares dilutes existing owners' stakes and signals a need for cash, sending BBNX down 8% after hours.
It is a direct, company-specific event that immediately pressures the share price through dilution.
Mint pump FDA clearance offset by 2026 revenue guidance cut Beta Bionics won FDA clearance for its Mint patch pump and submitted a next-gen dosing algorithm, key product milestones. But it cut 2026 revenue guidance to $121–$126 million from $131–$136 million, warning that some iLet customers may delay purchases before Mint launches. Shares jumped 15% on the news but remain down 27% year to date.
It captures the central tension this period: a major product win versus a near-term sales shortfall.
New CGM partnerships expand iLet ecosystem Beta Bionics partnered with Senseonics to add Eversense 365 continuous glucose monitoring to its iLet platform, expected to launch in late 2026. Combined with Abbott's new dual glucose-ketone sensor gaining FDA authorization and planned iLet compatibility, these deals broaden the iLet's appeal and could support future demand.
It shows concrete steps to strengthen the product ecosystem, a positive long-term driver for BBNX.

August 202625 Jul – 29 Sep 2026

▼2▲1

Mint pump cleared, but dilution and guidance cut weigh on BBNX

Fair value cut on medtech valuation reset Analysts slashed Beta Bionics' fair value estimate to $19.80 from $31.30, citing slower revenue growth, thinner profit margins and a much lower assumed future P/E multiple. This reset reflects broad medtech sector headwinds and pulled the stock's perceived worth down, even as some banks raised targets.
It explains the sharp drop in the stock's assessed value and the cautious backdrop for BBNX.
$125M stock offering dilutes shareholders Beta Bionics announced a $125 million public offering of new common stock, with an option for underwriters to buy up to $18.75 million more. Selling new shares dilutes existing owners' stakes and signals a need for cash, sending BBNX down 8% after hours.
It is a direct, company-specific event that immediately pressures the share price through dilution.
Mint pump FDA clearance offset by 2026 revenue guidance cut Beta Bionics won FDA clearance for its Mint patch pump and submitted a next-gen dosing algorithm, key product milestones. But it cut 2026 revenue guidance to $121–$126 million from $131–$136 million, warning that some iLet customers may delay purchases before Mint launches. Shares jumped 15% on the news but remain down 27% year to date.
It captures the central tension this period: a major product win versus a near-term sales shortfall.
New CGM partnerships expand iLet ecosystem Beta Bionics partnered with Senseonics to add Eversense 365 continuous glucose monitoring to its iLet platform, expected to launch in late 2026. Combined with Abbott's new dual glucose-ketone sensor gaining FDA authorization and planned iLet compatibility, these deals broaden the iLet's appeal and could support future demand.
It shows concrete steps to strengthen the product ecosystem, a positive long-term driver for BBNX.

Latest25 Jul – 29 Sep 2026

▼2▲1

Mint pump cleared, but dilution and guidance cut weigh on BBNX

Fair value cut on medtech valuation reset Analysts slashed Beta Bionics' fair value estimate to $19.80 from $31.30, citing slower revenue growth, thinner profit margins and a much lower assumed future P/E multiple. This reset reflects broad medtech sector headwinds and pulled the stock's perceived worth down, even as some banks raised targets.
It explains the sharp drop in the stock's assessed value and the cautious backdrop for BBNX.
$125M stock offering dilutes shareholders Beta Bionics announced a $125 million public offering of new common stock, with an option for underwriters to buy up to $18.75 million more. Selling new shares dilutes existing owners' stakes and signals a need for cash, sending BBNX down 8% after hours.
It is a direct, company-specific event that immediately pressures the share price through dilution.
Mint pump FDA clearance offset by 2026 revenue guidance cut Beta Bionics won FDA clearance for its Mint patch pump and submitted a next-gen dosing algorithm, key product milestones. But it cut 2026 revenue guidance to $121–$126 million from $131–$136 million, warning that some iLet customers may delay purchases before Mint launches. Shares jumped 15% on the news but remain down 27% year to date.
It captures the central tension this period: a major product win versus a near-term sales shortfall.
New CGM partnerships expand iLet ecosystem Beta Bionics partnered with Senseonics to add Eversense 365 continuous glucose monitoring to its iLet platform, expected to launch in late 2026. Combined with Abbott's new dual glucose-ketone sensor gaining FDA authorization and planned iLet compatibility, these deals broaden the iLet's appeal and could support future demand.
It shows concrete steps to strengthen the product ecosystem, a positive long-term driver for BBNX.

Zhonghong Pulin Medical Products Co. Ltd. (300981.CS)

Q3 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

August 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

Latest28 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.